Clinical Trials Logo

Thyroid Neoplasms clinical trials

View clinical trials related to Thyroid Neoplasms.

Filter by:

NCT ID: NCT06261190 Not yet recruiting - Thyroid Cancer Clinical Trials

Active Surveillance for Low-risk Papillary Thyroid Carcinoma

MAeSTro?
Start date: March 4, 2024
Phase:
Study type: Observational

This study is an observational cohort study targeting patients with low-risk Papillary thyroid cancer who opted for active surveillance or immediate surgery based on a sufficient understanding of the treatment options. The primary objective of the study is to evaluate progression free survival of the patients with low-risk Papillary thyroid cancer who choose active surveillance, in other words, to observe the natural course of low-risk Papillary thyroid cancer.

NCT ID: NCT06254859 Recruiting - Thyroid Cancer Clinical Trials

Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery

Start date: March 1, 2024
Phase:
Study type: Observational

This study examines the impact of intraoperative recurrent laryngeal nerve monitoring signal changes on the postoperative voice quality of thyroid surgery patients. By analyzing extensive surgical data and postoperative voice recordings, the investigation seeks to identify patterns in the variations of these signals and their correlation with voice quality outcomes. The goal is to enhance clinical understanding and surgical practices, allowing for more precise assessments of nerve function, informed surgical interventions, and improved postoperative patient well-being.

NCT ID: NCT06243965 Completed - Clinical trials for Medullary Thyroid Cancer

Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?

DSR-MTC
Start date: January 1, 1997
Phase:
Study type: Observational

The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) levels has been questioned due to the potential post-operative complications. This study aims to evaluate desmoplastic reaction (DSR), as predictor of nodal metastases, for definition of surgical strategy. Data from pathological report of MTC after operations between 1997 and 2022 were collected. The primary endpoint of the study was evaluating the risk factors for nodal metastases. The secondary endpoints analyzed the correlations between DSR and nodal metastases and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of DSR for nodal metastases.

NCT ID: NCT06241092 Recruiting - Clinical trials for Papillary Thyroid Carcinoma; Molecular Heterogeneity; Multi-model Analysis; Artificial Intelligence; Lymph Node Metastases; Disease-free Survival

AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid Carcinoma

Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

This study involved a comprehensive analysis of 256 PTC patients from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSMH) and 499 patients from The Cancer Genome Atlas. DNA-based next-generation sequencing (NGS) and single-cell RNA sequencing (scRNA-seq) were employed to capture genetic alterations and TME heterogeneity. A deep learning multimodal model was developed by incorporating matched histopathology slide images, genomic, transcriptomic, immune cells data to predict LNM and disease-free survival (DFS).

NCT ID: NCT06235814 Recruiting - Clinical trials for Papillary Thyroid Cancer

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

MAPS
Start date: July 30, 2024
Phase: N/A
Study type: Interventional

Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investigators hypothesize that patients will 1) agree to preoperative molecular analysis, and 2) 50% of intermediate-risk patients will agree to and follow through with randomization. This will be a pilot study for a future randomized controlled trial (RTC) to compare between the two surgical approaches in intermediate-molecular risk thyroid cancer.

NCT ID: NCT06235216 Not yet recruiting - Clinical trials for Differentiated Thyroid Cancer

Sacituzumab govitEcan in THYroid Cancers

SETHY
Start date: February 2024
Phase: Phase 2
Study type: Interventional

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

NCT ID: NCT06222606 Recruiting - Thyroid Cancer Clinical Trials

Surgery for Thyroid Cancer With or Without Autofluorescence to Prevent Hypoparathyroidism

Start date: January 2024
Phase: N/A
Study type: Interventional

The study aims to test if use of autofluorescence imaging (AF) reduces the risk of developing hypoparathyroidism (hypoPT) following surgery for thyroid cancer, either total thyroidectomy (TT) or completion hemithyroidectomy (cHT).

NCT ID: NCT06220656 Not yet recruiting - Thyroid Cancer Clinical Trials

TRAIL Study: Feasibility and Pilot

Start date: March 2024
Phase: N/A
Study type: Interventional

This is a pilot study to compare two ways of managing newly identified thyroid nodules that are likely to be cancerous based on ultrasound result and which under usual care would undergo immediate biopsy. The main goals of this pilot study are 1) compare anxiety at 6 months in each treatment arm using the validated instrument Anxiety-CA, 2) measure thyroid quality of life in each treatment arm Participants will be randomized to one of two groups: 1. immediate biopsy (usual care) 2. Active monitoring (serial ultrasound based monitoring and close clinical follow-up)

NCT ID: NCT06207188 Recruiting - Clinical trials for Thyroid Gland Carcinoma

Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters

Start date: May 17, 2009
Phase:
Study type: Observational

This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.

NCT ID: NCT06195228 Recruiting - Clinical trials for Advanced Thyroid Cancer Patients Who Received Target Therapy

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in our hospital from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in our hospital from January 2024 to April 2027 were enrolled.